Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL1025918 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| SCHEMBL1979 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL366444 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Ammonia Solution, Strong SCHEMBL6136995 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Bromide SCHEMBL1999327 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| SCHEMBL3210302 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| SCHEMBL4727402 | 0.92 | ALDH1A1 (0.44) | ALDH1A1TAAR1 | |
| Trimethylammonium SCHEMBL4940105 | 0.86 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL4787789 | 0.86 | ALDH1A1 (0.39) | ALDH1A1 | |
| Dimethylamine SCHEMBL6889985 | 0.83 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2493297-A1 | HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050215777-A1 | Synthesizing nucleic acid, contacting with a alkylamine, loading mixture onto media and applying a purification gradient using a suitable elution buffer; one pot deprotection; solution phase synthesis; solid phase synthesis | SIRNA THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1539778-A2 | DEPROTECTION AND PURIFICATION OF OLIGONUCLEOTIDES AND THEIR DERIVATIVES | Sirna Therapeutics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6841507-B2 | Aminonitrile production | INVISTA NORTH AMERICA S.A.R.L. (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040102644-A1 | Aminonitrile production | INVISTA NORTH AMERICA S.A.R.L. | 2004-05-27 | — | — | US | disclosed |
| US-6737540-B2 | Aminonitrile production | E. I. DUPONT DE NEMOURS AND COMPANY | 2004-05-18 | — | — | US | disclosed |
| US-20040048251-A1 | Deprotection and purification of oligonucleotides and their derivatives | SIRNA THERAPEUTICS, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004007748-A2 | DEPROTECTION AND PURIFICATION OF OLIGONUCLEOTIDES AND THEIR DERIVATIVES | SIRNA THERAPEUTICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030171609-A1 | Aminonitrile production | INVISTA NORTH AMERICA S.A.R.L. | 2003-09-11 | — | — | US | disclosed |
| US-6569802-B1 | Catalyst for selective hydrogenation of dinitriles | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | ALDH1A1 408/4885TAAR1 2135/4885 |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | ALDH1A1 1468/4885TAAR1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.